Trial Profile
APG101 in Transfusion-Dependent Patients With Low or Intermediate Risk Myelodysplastic Syndrome
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Asunercept (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Apogenix
- 28 Mar 2024 Results assessing the effect of Asunercept therapy on the clonal bone marrow composition to identify potential biomarkers to predict response published in the Annals of Hematology
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 05 Dec 2016 Results published in the Media Release